Literature DB >> 2150771

Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.

J K Blusztajn1, I Lopez Gonzalez-Coviella, M Logue, J H Growdon, R J Wurtman.   

Abstract

Concentrations of glycerophosphocholine and of glycerophosphoethanolamine, the metabolites of two major membrane phospholipid classes, phosphatidylcholine and phosphatidylethanolamine respectively, were determined post-mortem in cortical areas 20 and 40 and in cerebellum and caudate nucleus of brains obtained at autopsy from patients with Alzheimer's disease, Down's syndrome and age-matched control subjects. Glycerophosphocholine concentrations in all of the brain regions examined were higher by 67-150% in Alzheimer's disease than in control brains and 81-104% higher in Alzheimer's disease than in Down's syndrome. Glycerophosphoethanolamine concentrations were 21-52% higher in Alzheimer's disease than in controls, and 27-92% higher in Alzheimer's disease than Down's syndrome. Levels of glycerophosphocholine and of glycerophosphoethanolamine did not differ significantly between Down's syndrome and control brains. These data indicate that abnormal phospholipid metabolism in brain is characteristic of Alzheimer's disease but not Down's syndrome and suggest that this abnormality may be a central pathophysiological feature of Alzheimer's disease because levels of glycerophosphocholine and of glycerophosphoethanolamine are elevated in brain regions with and without manifestations of histopathology.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150771     DOI: 10.1016/0006-8993(90)90030-f

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

1.  Quantitation of glycerophosphorylcholine by flow injection analysis using immobilized enzymes.

Authors:  A Mancini; F Del Rosso; R Roberti; P Caligiana; A Vecchini; L Binaglia
Journal:  Mol Cell Biochem       Date:  1996-09-20       Impact factor: 3.396

2.  Sexually dimorphic activation of liver and brain phosphatidylethanolamine N-methyltransferase by dietary choline deficiency.

Authors:  P I Johnson; J K Blusztajn
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  Regional membrane phospholipid alterations in Alzheimer's disease.

Authors:  M R Prasad; M A Lovell; M Yatin; H Dhillon; W R Markesbery
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

Review 4.  Alkyl-Acylglycerols and the Important Clinical Ramifications of Raising Plasmalogens in Dementia and Alzheimer's Disease.

Authors:  Chris D Meletis
Journal:  Integr Med (Encinitas)       Date:  2020-06

Review 5.  Alois Alzheimer revisited: differences in origin of the disease carrying his name.

Authors:  K Maurer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

6.  Active site of brain Zn2+-glycerophosphocholine cholinephosphodiesterase and regulation of enzyme activity.

Authors:  D E Sok
Journal:  Neurochem Res       Date:  1998-08       Impact factor: 3.996

7.  Phospholipase D-catalyzed hydrolysis of phosphatidylcholine provides the choline precursor for acetylcholine synthesis in a human neuronal cell line.

Authors:  H C Lee; M P Fellenz-Maloney; M Liscovitch; J K Blusztajn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

8.  Activation of LA-N-2 cell phospholipase D by amyloid beta protein (25-35).

Authors:  I N Singh; G Sorrentino; J N Kanfer
Journal:  Neurochem Res       Date:  1998-10       Impact factor: 3.996

9.  Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls.

Authors:  J N Kanfer; J W Pettegrew; J Moossy; D G McCartney
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

10.  Effects of lysophosphatidylcholine on beta-amyloid-induced neuronal apoptosis.

Authors:  Zhen-xia Qin; Hui-yan Zhu; Ying-he Hu
Journal:  Acta Pharmacol Sin       Date:  2009-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.